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Longer‑term (≥ 2 years) survival 
in patients with glioblastoma 
in population‑based studies pre‑ 
and post‑2005: a systematic review 
and meta‑analysis
Michael T. C. Poon1,2, Cathie L. M. Sudlow1,2,3, Jonine D. Figueroa1,2 & Paul M. Brennan2,3*
Translation of survival benefits observed in glioblastoma clinical trials to populations and to longer‑
term survival remains uncertain. We aimed to assess if ≥ 2‑year survival has changed in relation 
to the trial of radiotherapy plus concomitant and adjuvant temozolomide published in 2005. We 
searched MEDLINE and Embase for population‑based studies with ≥ 50 patients published after 2002 
reporting survival at ≥ 2 years following glioblastoma diagnosis. Primary endpoints were survival 
at 2‑, 3‑ and 5‑years stratified by recruitment period. We meta‑analysed survival estimates using 
a random effects model stratified according to whether recruitment ended before 2005 (earlier) or 
started during or after 2005 (later). PROSPERO registration number CRD42019130035. Twenty‑
three populations from 63 potentially eligible studies contributed to the meta‑analyses. Pooled 
2‑year overall survival estimates for the earlier and later study periods were 9% (95% confidence 
interval [CI] 6–12%; n/N = 1,488/17,507) and 18% (95% CI 14–22%; n/N = 5,670/32,390), respectively. 
Similarly, pooled 3‑year survival estimates increased from 4% (95% CI 2–6%; n/N = 325/10,556) to 
11% (95% CI 9–14%; n/N = 1900/16,397). One study with a within‑population comparison showed 
similar improvement in survival among the older population. Pooled 5‑year survival estimates 
were 3% (95% CI 1–5%; n/N = 401/14,919) and 4% (95% CI 2–5%; n/N = 1,291/28,748) for the earlier 
and later periods, respectively. Meta‑analyses of real‑world data suggested a doubling of 2‑ and 
3‑year survival in glioblastoma patients since 2005. However, 5‑year survival remains poor with no 
apparent improvement. Detailed clinically annotated population‑based data and further molecular 
characterization of longer‑term survivors may explain the unchanged survival beyond 5 years.
Glioblastoma multiforme is the most common primary malignant brain tumour in adults with an incidence rate 
of 3.7 per 100,000 person-years, though geographical variation  exists1. Despite an increasing understanding of the 
underlying pathophysiology, glioblastoma remains an incurable disease with high  mortality2. A landmark clinical 
trial in 2005 demonstrated that the addition of concomitant and adjuvant temozolomide to radiotherapy provided 
an additional survival benefit to patients diagnosed with  glioblastoma3. Multiple clinical trials had investigated 
novel therapies that showed promise in pre-clinical and early phase studies, but to date there have been no major 
additions to the treatment armamentarium for newly diagnosed patients since 2005. The median survival in the 
intervention arm of the 2005 trial was 14.6 months3, but there is uncertainty about whether survival benefit from 
clinical trials is translated to the  population4,5. Clinical trial participation itself is associated with better  survival6, 
which may be caused by the preferential inclusion and exclusion criteria into clinical trials. In clinical practice 
not all patients are eligible for the trial standard of care involving maximal surgical debulking, chemotherapy 
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and radiotherapy, for example because of co-morbidities, poor functional status or tumour location within the 
brain. There is also a paucity of data on long-term GBM survivors.
We systematically reviewed population-based studies that reported overall survival after glioblastoma to 
characterize survival beyond 2 years and investigate whether survival has changed since the landmark 2005 trial.
Methods
Protocol and registration. We registered this systematic review in PROSPERO (CRD42019130035) and 
reported it in accordance with PRISMA and MOOSE guidelines.
Eligibility criteria. We included all population-based studies reporting overall survival at ≥ 2  years in 
adults with glioblastoma. Studies reporting overall survival in all types of brain tumor from which data could 
be extracted for glioblastoma were also eligible. There was no language restriction. We excluded conference 
abstracts, studies without data on overall survival at ≥ 2 years, studies with less than 50 participants, and studies 
published before 2003 because contemporary imaging facilities and provision, which impact on time of diagno-
sis and patient management, were generally not available during their recruitment periods.
Information sources and search. We searched MEDLINE and Embase on 15 March 2019 using a com-
bination of search terms for glioma or glioblastoma, population-based, registry, and survival or mortality (Sup-
plementary material Appendix 1). We screened bibliographies of eligible studies for any studies missed by the 
electronic searches.
Study selection. After removing duplicate records, two reviewers (MTCP and PMB) screened all titles 
and abstracts. Studies passing the initial screening underwent full eligibility assessment against the inclusion 
and exclusion criteria. We resolved any disagreements or uncertainties through discussion between the authors.
Data collection process. We developed a data collection tool using a subset of eligible studies. One 
reviewer (MTCP) extracted data from eligible studies against the data collection tool. A second reviewer (PMB 
or JDF) resolved uncertainties by discussion.
Data items. We collected data on study characteristics including year of publication, country of population, 
registry or database used, recruitment period, any study-specific selection criteria, total sample size, median age, 
gender, number and proportion of patients receiving different treatments (surgical resection, chemotherapy, 
radiotherapy), and number and proportion of patients surviving at 2, 3, 5, and 10 years. As cancer registries 
generally do not routinely collect the specific chemotherapy drug and its regimen, we could not quantify the 
proportion of patients receiving multimodal therapy. If a study reported survival data stratified by recruitment 
period, we extracted the stratified survival data. Therefore, a study may contribute to meta-analyses of more than 
one recruitment period. When studies only reported survival data on a graph, we used Plot Digitizer (https ://
plotd igiti zer.sourc eforg e.net/) to extract data.
Risk of bias assessment. As there is no published risk of bias tool specifically for evaluating population-
based observational studies without a pre-defined exposure, we assessed risk of bias based on the preliminary 
ROBINS-E tool developed by  GRADE7, 8. The assessment aimed to evaluate the risk of bias affecting the sur-
vival estimate in the study. Categories assessed for bias were patient selection, diagnostic certainty, handling of 
missing data, and outcome measurement (Supplementary Table S1). Based on risk of bias assessment in each 
category, we rated the overall risk of bias as low, moderate, serious, or critical.
Summary measures. Summary measures were proportions of patients with glioblastoma surviving at 2, 
3, 5, and 10 years.
Synthesis of results. We stratified studies according to whether the recruitment period was before 2005 
or during or after 2005 as a proxy to wider use of multimodal treatment in the later period, informed by the 
2005 landmark trial. This dichotomy does not imply a definite use of multimodal treatment since not all patients 
received this treatment and clinical practice of offering this treatment varies. If several publications described the 
same population, we included the largest sample size. Our target population was all individuals diagnosed with 
glioblastoma, therefore we excluded studies with selected cohorts—for example, additional exclusion criteria 
based on age or treatment limit—from the meta-analyses. We meta-analysed survival data at 2, 3, and 5 years 
from population-based studies stratified by recruitment period using Stata 16.0 (StataCorp) using a random-
effects model. We quantified heterogeneity using the  I2 statistic.
Additional analyses. By analysing non-overlapping patients stratified by recruitment period, we inevitably 
excluded some studies from the meta-analyses. Additional analyses of these excluded studies with recruitment 
period starting before and ending after 2005 allowed us to compare their pooled estimates with the primary 
analyses. Sensitivity analyses restricting to low risk of bias studies assessed how this affected the meta-analyses.
We observed that survival estimates from East Asian studies appeared higher than European and North 
American studies. To assess the contribution of the East Asian studies to the heterogeneity observed, we per-
formed sensitivity analyses by meta-analysing the same survival data without studies of East Asian populations.
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Further sensitivity analyses included moving the proxy year to 2006 to represent the time-point after which 
multimodal treatment was likely to be more common. We also meta-analysed studies where patient recruit-
ment started before and ended after 2005. These studies contained some patients also included within popula-
tions contributed to the main analyses. However, no patients were included more than once in this additional 
meta-analysis.
Results
Study selection and characteristics. Our search strategy retrieved 503 records. There were 135 poten-
tially eligible studies, of which 63 were included in this review after full eligibility assessment (Fig. 1)9–37. One 
study reported two distinct  populations14. Therefore, there were 63 eligible studies representing 64 populations 
from 17 countries that reported overall survival at ≥ 2 year in patients with glioblastoma. Detailed study char-
acteristics are presented in Supplementary Table S2 (p 4–7). The United States was the most frequently reported 
population (n = 29; 45%). Twenty-seven studies reported survival estimates in Western European populations 
(including Switzerland and the United Kingdom), and three in Canada. Of the remaining studies, four were 
from East Asian populations and one from Australia. The median length of recruitment period was 8.5 years 
(IQR 5–14 years). Median age ranged from 58 to 75 years. In studies that did not use the predominantly male 
Veterans Health Administration (VA) database, the percentage of females ranged from 32 to 61%. The percent-
age of patients receiving each of the following treatments ranged from 25 to 100% for resective surgery; 39–100% 
for radiotherapy; 7–100% for chemotherapy. There were 55 (87%) studies reporting 2-year survival, 31 (49%) 
reporting 3-year survival, 32 (51%) reporting 5-year survival, and 3 (5%) reporting 10-year survival.
Risk of bias. Based on our risk of bias assessment, 29 (46%) studies had low risk of bias (Supplementary 
Table S2). Nine studies included glioblastoma cases without histological confirmation. Fourteen studies (22%) 
had a sample size of less than 300. Demographic information (age and gender) were provided in 30 (48%) stud-
ies. Only 21 (33%) studies reported the proportion of patients receiving each of resective surgery, radiotherapy, 
and chemotherapy.
2‑year survival. Sixty-seven survival data points stratified by recruitment period were available from 55 
studies reporting 2-year survival. There were 16 survival estimates for patients recruited before 2005, 30 for those 
recruited in studies that spanned across 2005, and 21 for those recruited during or after 2005. After reviewing 
the information sources for the sample sizes of these studies, survival data from non-overlapping patients were 
available in eight studies where patient recruitment ended before 2005, and 13 where recruitment started in or 
after 2005. Table 1 shows the characteristics of these studies. The pooled 2-year survival estimate for the earlier 
period was 9% (95% confidence interval [CI] 6–12%; n/N = 1,488/17,507;  I2 = 97.2%; Fig. 2); the pooled estimate 
for the later period was 18% (95% CI 14–22%; n/N = 5,670/32,390;  I2 = 98.3%; Fig. 2). Seven populations had 
Medline Search
N=287
Embase Search
N=358
Hand Search
 N=11
Records after removing duplicates
N=503
Records screened
N=503
Full-text eligibility assessment
N=135
Qualitative analysis
N=63
Quantitative analysis
N=22
Excluded
N=368
Full-text articles excluded (N=72)
• Not reporting overall survival (n=43)
• Published before 2003 (n=14)
• Sample size <50 (n=1)
• Non-population-based cohort (n=2)
• Review (n=1)
Figure 1.  PRISMA flowchart.
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2-year survival available at both the earlier and later periods, enabling within-population comparisons: Surveil-
lance, Epidemiology, and End Results (SEER) in the  US13,31, Veterans Health Administration (VA) in the  US15, 
 Italy26,35,  Switzerland18,28,  France9,17,  Sweden16,24 and  Korea22. The survival estimates were higher during the later 
period compared with the earlier period in all seven populations. Three studies observed at least doubling of 
survival. The increase in survival ranged from 2 to 8% in the other studies.
3‑year survival. Thirty-five survival data points were available from 31 studies reporting 3-year survival. 
There were nine survival estimates for patients recruited before 2005, 16 for those where recruitment spanned 
across 2005, and ten for those recruited during or after 2005. There were seven studies contributing to each meta-
analysis for the earlier and later period (Table 1). Pooled 3-year survival was 4% (95% CI 2–6%; n/N = 325/10,556; 
 I2 = 97.9%; Fig. 3) for the earlier period, and 11% (95% CI 9–14%; n/N = 1900/16,397;  I2 = 91.8%; Fig. 3) for the 
later period. There was at least doubling of 3-year survival in all four populations  (SEER20,21,  VA15,  Italy10,26, and 
 Sweden16) that allowed a within-population comparison.
5‑year survival. Thirty-seven survival data points were available from 32 studies reporting 5-year survival. 
There were seven survival estimates for patients recruited before 2005, 22 for those recruited in studies that 
spanned across 2005, and seven for those recruited during or after 2005. Meta-analyses from five studies (with 
no duplicated patients) in each time period (Table 1) yielded pooled survival estimate of 3% (95% CI 1–5%; 
n/N = 401/14,919;  I2=96.6%; Fig. 4) for the earlier period, and 4% (95% CI 2–5%; n/N = 1,291/28,748;  I2 = 98.0%; 
Fig. 4) for the later period. The US  VA15 and  SEER13,31 populations allowed within-population comparison. Sur-
vival increased from  213 to 6%31 in the SEER population but remained at 1% in the VA  population15.
10‑year survival. Only 3 (5%) studies reported 10-year  survival29,33,37. Two studies used the United States 
SEER  database33,37, while one was from Canada using a national cancer  registry37. The recruitment periods 
Table 1.  Study characteristics of 22 eligible studies included in the quantitative analyses. GBM glioblastoma 
multiforme, RoB risk of bias, HDx all cases with histological diagnosis, SR surgical resection, ChT 
chemotherapy, RT radiotherapy, KPS Karnofsky Performance Score, TMZ temozolomide, NOS not otherwise 
specified, yr years, % percentage, VA Veterans Health Administration, SEER Surveillance, Epidemiology and 
End Results Program, OH Ohio, CA California, NC North Carolina. a This is a single study reporting survival 
data on two separate populations of GBM patients. b This denotes the analyses in which the study contributed 
survival data; E = recruitment before 2005 (earlier); L = recruitment during or after 2005 (later). c Risk of 
bias relates to survival estimate reported in the study. Scores are based on assessment of patient selection, 
diagnostic certainty, handling of missing data and outcome measurement. Studies are categorized into four 
risk of bias groups: (1) low; (2) moderate; (3) serious; (4) critical. d Median or mean age of cohort in years 
depending on which was reported in the study.
Study Country Recruitment Periodb RoBc HDx N Aged % female % SR % ChT % RT 2 yr 3 yr 5 yrs
Bauchet (2010)9 France 2004–2004 E 1 1 952 64 38 56 59 68 ● – –
Chang (2005)13 US (SEER) 1988–2001 E 3 1 10,987 64 43 74 – 74 ● – ●
Iwamoto (2008)20 US (SEER) 1994–2002 E 4 1 5,909 – 55 70 7 45 ○ ● ○
Mathiesen (2011)24 Sweden 1996–2001 E 1 1 1,110 – – – – – ● – –
Nava (2014)26 Italy 1997–2010 E 1 1 1,254 – 36 91 – – ● ● ●
Ohgaki (2004)28 Switzerland 1980–1994 E 3 0 715 61 – – – – ● ● –
Rosenthal (2006)32 Australia 1998–2000 E 2 1 473 – – – – – ● ● ●
Dubrow (2013)15 US (VA) 1997–2008 E & L 1 1 1645 – 3 74 43 73 ● ● ●
Eriksson (2019)16 Sweden (Umeå) 1995–2015 E & L 1 1 571 – 38 – – – ○ ● ●
Jung (2012)22 Korea 1999–2007 E & L 1 1 2,751 – – – – – ● ● ●
Brandes (2014)10 Italy 2001–2013 L 4 1 139 59 38 – 100 100 ○ ● –
Brodbelt (2015)11 UK 2007–2011 L 1 1 10,743 57 40 80 25 – ● – ●
Bruhn (2018)12 Sweden (Jönköping) 2001–2005 L 2 1 143 – 38 34 – – ● – –
Chien (2015)14,a Taiwan 2007–2012 L 1 1 908 – – – – – ● – –
Fabbro-Peray 
(2018)17 France 2008–2008 L 1 1 2053 64 40 59 90 90 ● – ●
Gramatzki (2016)18 Switzerland 2005–2009 L 1 1 264 61 38 81 60 70 ● ● –
Graus (2013)19 Spain 2008–2010 L 2 1 834 62 39 66 61 72 ● ● –
Johnson (2018)21 US (SEER) 2006–2012 L 1 1 12,873 – 41 61 51 75 ○ ● –
Morgan (2017)25 Canada 2006–2012 L 1 1 138 61 39 83 65 87 ● – –
Rasmussen (2018)30 Denmark 2009–2014 L 1 1 1,364 64 61 – – – ● ● ●
Rong (2016)31 US (SEER) 2007–2012 L 4 0 13,665 63 42 76 – 60 ● – ●
Salmaggi (2008)35 Italy (Lombardy) 2005–2005 L 3 0 349 60 36 70 100 89 ● – –
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ranged from 9 to 16 years. Each study had more than 10,000 patients. All three studies had serious or critical 
risk of bias for their survival estimates. Both studies from the United States included reported survival only in 
patients who had surgical resection, and one of them excluded those who died within 1 month of surgery. About 
25% patients in the Canadian study did not have a histological diagnosis of glioblastoma. The estimate of 10-year 
survival ranged from 0.333 to 3%37. No comparison in relation to 2005 was possible as all study periods started 
before and ended after 2005.
Sensitivity analyses. Restricting quantitative analyses to low risk-of-bias studies showed the respective 
pooled survival estimates for the earlier and later periods were: 11% and 18% at 2 years; 5% and 8% at 3 years; 
and 3% and 3% at 5 years (Supplementary Fig. S1). Because survival estimates from East Asian populations were 
consistently higher than the pooled estimate, we carried out sensitivity analyses excluding the East Asian studies 
from meta-analyses. The respective pooled survival estimates without the East Asian populations for the earlier 
and later periods were: 8% and 16% at 2 years; 2% and 11% at 3 years; and 2% and 4% at 5 years (Supplementary 
Fig. S2). Instead of using year 2005 as a proxy time-point after which wider use of multimodal therapy occurred, 
we stratified studies by their recruitment period into before 2006, and during or after 2006. There was no change 
to the number of studies available for meta-analyses in the earlier period. In the later period, meta-analyses at 2, 
3 and 5 years had 5, 3, and 1 fewer studies, respectively. The respective pooled survival estimates for the earlier 
and later period using 2006 as the proxy time-point were: 9% and 19% at 2 years; 4% and 12% at 3 years, and 3% 
and 4% at 5 years (Supplementary Fig. S3).
Meta-analyses of studies that did not contribute to the main analyses are presented in Supplementary Material 
(Fig. S4). These studies contain some overlapping patients with populations in the main analyses. The pooled 
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Figure 2.  Forest plots of 2-year overall survival stratified by recruitment period.
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estimates of the proportion of patients surviving at 2 and 3 years were 12% and 8%, respectively. Both were 
between the pooled estimates for the earlier and later periods. At 5 years, the pooled estimate was 4%.
Older populations. Regardless of recruitment period, there were five studies that restricted their cohorts to 
patients ≥ 65 years20,27,34 and ≥ 70 years of  age23,36. Populations in these studies were based in the United States—
four from  SEER20,27,34,36 and one from the National Cancer Database (NCDB)23. The 2-year survival estimates 
ranged from  220 to 11%23, and 3-year survival ranged from 0.420,36 to 5%23. The 5-year survival was 0.2% in the 
only study reporting at this time  point20. One study had within-population comparison for the earlier and later 
recruitment periods and reported an increase in survival estimate at 2 and 3 years from 2 to 7% and from 0.9 to 
3%,  respectively36.
Discussion
This systematic review of 63 population-based studies of which 22 were included in the primary analyses found 
that 2-year survival was 18%, 3-year survival was 11%, and 5-year survival was 4% in patients diagnosed with 
glioblastoma during or after 2005. There was a doubling of 2- and 3-year survival in contemporary populations 
compared with patients treated prior to 2005. These survival gains were also evident in older (≥ 65 years) patients. 
However, there was no apparent improvement in 5-year survival.
The most significant development in clinical management of glioblastoma in the past two decades has been 
the landmark trial of radiotherapy plus concomitant and adjuvant  temozolomide3. This clinical trial among 573 
patients with a median follow-up of 28 months demonstrated that when compared with radiotherapy alone, the 
combination therapy improved the median survival from 12.1 to 14.6 months. The reported 2-year survival was 
8% in the radiotherapy alone group, and 20% in the combination therapy group. These survival probabilities are 
very similar to our findings for 2-year survival from the meta-analyses of earlier and later time periods. Within-
population comparisons, which should be less prone to confounding, confirmed a higher survival in the later 
versus earlier period. Although it is not possible to directly examine whether this improvement is secondary to 
the use of multimodal therapy, there was a rapid increase in the use of adjuvant and concomitant temozolomide 
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Figure 3.  Forest plots of 3-year overall survival stratified by recruitment period.
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with radiotherapy after the trial  publication38, at least in the United States. The  European39,40 and the United 
 States41 neuro-oncology guidelines have established multimodal treatment for glioblastoma as the standard of 
care in many countries. Hence, it is possible that the increased use of multimodal therapy contributed to the 
improvements observed. Our findings also demonstrate the value of using health data to assess the impact of 
therapeutic advances on a disease at a population level. This approach can evaluate the real-world risk–benefit 
ratio of treatment at scale for treatments that have significant side-effects.
International variations in incidence of malignant  astrocytoma42 and overall survival, may suggest different 
aetiologies, underlying disease processes, or risk exposure such as  ethnicity1. Investigations into these factors may 
elucidate different underlying pathological mechanisms. Differences in cancer registration practice could also 
contribute to survival variation. The International Cancer Benchmarking Partnership (ICBP), which comprises 13 
jurisdictions from 6 countries, has reported differences in capturing incidence  date43. Furthermore, the increased 
use of brain  imaging44 and high prevalence of incidental  findings45 may further contribute to the lead-time bias.
There has been significant progress in understanding genomic drivers implicated in glioma tumorigenesis. 
Multidimensional data from genomics studies such as The Cancer Genome Atlas (TCGA)46, REMBRANDT 
 study47, and the Chinese Glioma Genome Atlas (CGGA)48 have identified molecular signatures associated with 
glioma subtypes and their  prognoses49. Isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion are 
most prominent markers associated with a more favourable  prognosis49. The importance of these markers are 
reflected in the 2016 update of the WHO classification of central nervous system (CNS)  tumours50, which 
incorporates molecular markers into the definition of tumour entities, in addition to histological features. Future 
studies should examine outcomes and therapy responses amongst these molecular subtypes.
Studying clinical phenotypes can gain knowledge of glioblastoma disease mechanisms. In a recent study 
using radiographical and transcriptomics data, it was suggested that female and male patients with glioblastoma 
have different molecular  mechanisms51. Studies have suggested that longer-term survivors may have different 
clinical and tumour characteristics compared to shorter-term survivors. Patients with glioblastoma surviving 
5 years or more are  younger52–54 and have better performance status at the time of  diagnosis53,54 compared with 
shorter-term survivors. Methylation of the  O6-methylguanine-DNA-methyltransferase (MGMT)55,56 and  IDH55 
mutation are more common in patients surviving 3 years compared with those who died before 3 years. However, 
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Figure 4.  Forest plots of 5-year overall survival stratified by recruitment period.
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studies of long-term survivors are challenging given that there are very few subjects, with a varying degree of 
clinical detail. The observation that the proportion of patients surviving 5 years has not changed, may indicate 
a molecularly distinct group of patients within this heterogeneous disease. In order to clarify this hypothesis, 
future studies should include comprehensive clinical details with molecular markers in a large patient cohort.
This systematic review and meta-analysis presented international real-world data drawn from population-
based studies. We evaluated longer-term survival beyond the median survival observed in the landmark trial, 
and we were able to compare survival in the era of contemporary management to an earlier period. Our data also 
addressed the survival uncertainty in the older population. However, there were some limitations to our study. A 
high proportion of eligible studies used the same national database. We adopted a strategy to prevent any patient 
from being included more than once in our analyses. Inevitably this led to the omission of patients recruited in 
some time periods. However, our sensitivity analyses comparing the pooled estimate of these omitted studies to 
that of the main analyses showed a confirmatory trend of survival improvement (Supplementary Fig. S4). There 
was considerable between-study heterogeneity despite excluding studies with a high risk of bias and examining 
heterogeneity in our sensitivity analyses. Unmeasured factors such as unrecorded variables, missing treatment 
data, and variations in data coding would contribute to the variation of survival  estimates57. Patients in some 
studies did not have histological confirmation; patients with better prognosis associated with lower grade gliomas 
or other brain tumours may have been included. This ascertainment bias is unlikely to have significantly affected 
our findings since studies in the meta-analyses, where some patients did not have histological confirmation, 
had similar survival to other studies. While this review examines the trend in survival in relation to a landmark 
clinical trial, we were unable to evaluate directly the pattern of treatment and its impact on survival due to 
limited treatment information available from eligible studies. Within-population comparison of different time 
periods, which may partially control for unmeasured factors, was only possible in a few eligible studies. We are, 
therefore, unable to directly attribute the survival trend observed to a change in treatment patterns. We used 
the year of 2005 as a proxy time-point for the introduction of wider use of multimodal therapy. Although some 
studies specified the more prevalent use of multimodal therapy, not all would have taken up recommendations 
from the clinical trial. However, our sensitivity analysis showed no substantial change in trend and having the 
cut-off year at 2005 allowed more studies to be included (Supplementary Fig. S3). Survival improvement may 
be attributable to other factors in addition to the multimodal treatment, such as more prevalent use of neuro-
imaging leading to earlier diagnosis, strengthening of multidisciplinary neuro-oncology care, and advances in 
neurosurgical techniques.
Conclusions
Overall estimates of survival among patients with glioblastoma have at least doubled since 2005 to 18% at 2 years 
and 11% at 3 years. This may reflect treatment response to modern therapeutic approaches. However, longer 
term survival remains poor and there appears to be a lack of improvement in 5-year survival. Large population-
based studies with detailed clinical characteristics would clarify whether there has been an increase in the use of 
multimodal therapy and whether multimodal therapy affects survival beyond 5 years. Differences in msolecular 
markers of tumour subtypes may shed light on the underlying disease mechanisms that influence survival.
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